Research paths to successful prevention and treatment of swine-derived H1N1 influenza virus infection

Drug News and Perspectives

Volumn 23, Issue 1, 2010, Pages 65-70

  Gómez Lucía, Esperanza ^a   Rodríguez, Fernando ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRE DE RECERCA EN SANITAT ANIMAL CRESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NITAZOXANIDE; OSELTAMIVIR; RIBAVIRIN;

ANTIVIRAL THERAPY; CHEMOTHERAPY; DRUG EFFICACY; HUMAN; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; NONHUMAN; PANDEMIC; REVIEW; SWINE INFLUENZA VIRUS; VIRUS MUTATION;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 77950638815     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.1.1416985     Document Type: Review

References (73)

1. Itoh, Y., Shinya, K., Kiso, M. et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460(7258): 1021-1025
2. Yang, Y., Sugimoto, J.D., Halloran, M.E. et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009, 326(5953): 729-733
3. Dowdle, W.R., Hattwick, M.A. Swine influenza virus infections in humans. J Infect Dis 1977, 136(Suppl. S): S386-9.
4. Butler, D. Swine flu goes global. Nature 2009, 458(7242): 1082-1083
5. Thacker, E., Janke, B. Swine influenza virus: Zoonotic potential and vaccination strategies for the control of avian and swine influenzas. J Infect Dis 2008,197(Suppl. 1): S19-24.
6. Kelly, H., Grant, K. Interim analysis of pan-demic influenza (H1N1) 2009 in Australia: Surveillance trends, age of infection and effectiveness of seasonal vaccination. Eurosurveillance 2009,14(31): 19288.
7. De Groot, A.S., Ardito, M., McClaine, E.M., Moise, L., Martin, W.D. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009, 27(42): 5740-5747
8. Capua, I., Cattoli, G. Flu: Vaccinate to cut risk of chimaeric virus emerging. Nature 2009, 460(7255): 571.
9. Palese, P. Making better influenza vims vaccines? Emerg Infect Dis 2006, 12(1): 61-65
10. Medlock, J., Galvani, A.P. Optimizing influenza vaccine distribution. Science 2009, 325(5948): 1705-1708
11. Battistini, A., Ollari, R., Dodi, L. Anti-influenza vaccination in children. Pediatr Med Chir 1985, 7(3): 369-374
12. Cox, RJ., Brokstad, K.A., Ogra, P. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(1): 1-15.
13. Banzhoff, A., Pellegrini, M., Del Giudice, G, Fragapane, E., Groth, N., Podda, A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses 2008, 2(6): 243-249
14. Herzog, C, Hartmann, K., Künzi, V., Kürsteiner, O., Mischler, R., Lazar, H., Glück, R. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27(33): 4381-4387
15. Murphy, B.R., Coelingh, K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15(2): 295-323.
16. Tosh, P.K., Boyce, T.G., Poland, CA. Flu myths: Dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc 2008, 83(1): 77-84.
17. Collin, N., de Radiguès, X. World Health Organization H1N1 Vaccine Task Force. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 2009, 27(38): 5184-5186
18. Enserink, M. Swine flu outbreak. Worries about Africa as pandemic marches on. Science 2009, 325(5941): 662.
19. Rieht, J.A., García-Sastre, A. Attenuated influenza virus vaccines with modified NS1 pro-teins. Curr Top Microbiol Immunol 2009, 333: 177-195
20. Masic, A., Booth, J.S., Mutwiri, G.K., Babiuk, L.A., Zhou, Y. Elastase-dependent live attenuated swine influenza A viruses are immunogenic and confer protection against swine influenza A virus infection in pigs. J Virol 2009, 83(19): 10198-10210
21. Zhou, B., Donnelly, M.E., Scholes, D.T., St George, K., Hatta, M., Kawaoka, Y., Wentworth, D.E. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol 2009, 83(19): 10309-10313
22. Perez, J.T., Pham, A.M., Lorini, M.H., Chua, M.A., Steel, J., tenOever, B.R. MicroRNA-mediated species-specific attenuation of influenza A virus. Nat Biotechnol 2009, 27(6): 572-576
23. Tripp, R.A., Tompkins, S.M. Recombinant vaccines for influenza virus. Curr Opin Investig Drugs 2008, 9(8): 836-845
24. Kopecky-Bromberg, S.A., Palese, P. Recombinant vectors as influenza vaccines. Curr Top Microbiol Immunol 2009, 333:243-67.
25. King, J.C Jr., Cox, M.M., Reisinger, K., Hedrick, J., Graham, I., Patriarca, P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009, 27(47): 6589-6594
26. Okamoto, S., Matsuura, M., Akagi, T. et al. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine 2009, 27(42): 5896-5905
27. Kang, S.M., Song, J.M., Quan, F.S., Compans, R.W. Influenza vaccines based on virus-like particles. Virus Res 2009, 143(2): 140-146
28. Kang, S.M., Pushko, P., Bright, R.A., Smith, G., Compans, R.W. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 2009, 333:269-289
29. Haynes, J.R. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009, 8(4): 435-445
30. Ross, TM., Mahmood, K., Crevar, C.J., Schneider-Ohrum, K., Heaton, P.M., Bright, R.A. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 2009, 4(6): e6032.
31. NewsRx™ website. www.newsrx.com/...07.../240716200924FL.html.
32. Carrat, F., Flahault, A. Influenza vaccine: The challenge of antigenic drift. Vaccine 2007, 25(39-40): 6852-6862
33. Roose, K., Fiers, W., Saelens, X. Pandemic preparedness: Toward a universal influenza vaccine. Drug News Perspect 2009, 22(2): 80-92.
34. Schotsaert, M., De Filette, M., Fiers, W., Saelens, X. Universal M2 ectodomain-based influenza A vaccines: Preclinical and clinical developments. Expert Rev Vaccines 2009, 8(4): 499-508.
35. Price, GE., Soboleski, M.R., Lo, C.Y et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27(47): 6512-6521
36. Assarsson, E., Bui, H.H., Sidney, J. et al. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 2008, 82(24): 12241-12251
37. Sui, J., Hwang, W.C, Perez, S. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009,16(3): 265-73.
38. Ng, W.C, Gilbertson, B., Lim, B. et al. Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza. Influenza Other Respi Viruses 2009, 3(4): 177-182
39. Teijaro, J.R., Njau, M.N., Verhoeven, D. et al. Costimulation modulation uncouples protection from immunopothology in memory T cell responses to influenza virus. J Immunol 2009, 182(11): 6834-6843
40. European Medicines Agency. Review on influenza antiviral medicinal products for potential use during pandemic. http://www.emea.europa.eu/pdfs/ human/pandemicin-fluenza/33997205en.pdf. Accessed January 12, 2010.
41. Food and Drug Administration. Influenza (Flu) Antiviral Drugs and Related Information. http://www.fda.gov/Drugs/DrugSafety/lnformationbyDrugClass/ ucml00228.htm. Accessed January 12, 2010.
42. Tumpey, T.M., García-Sastre, A., Mikulasova, A., Taubenberger, J.K., Swayne, D.E., Palese, P., Basier, CF. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sei U S A 2002, 99(21): 13849-13854
43. Moscona, A. Neuraminidase inhibitors for influenza. N Engl J Med 2005, 353(13): 1363-1373
44. Democratis, J., Pareek, M., Stephenson, I. Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother 2006, 58(5): 911-915
45. Centre for Disease Control. 2009-2010 Influenza season. Week 40 ending October 10, 2009. http://www.cdc.gov/flu/weekly/pdf/External-F0940.pdf. Accessed January 12, 2010.
46. Centre for Disease Control. Additional considerations to the interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-09 influenza season, http://www.cdc.gov/flu/professionals/antivirals/additional- considerations.htm. Accessed January 12, 2010.
47. Gubareva, L.V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004, 103(1-2): 199-203.
48. Hurt, A.C., Hotien, J.K., Parker, M., Kelso, A., Barr, I.G Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009, 83(20): 10366-10373
49. Besselaar, TC, Naidoo, D., Buys, A., Gregory, V., McAnerney, J., Manamela, J.M., Blumberg, L., Schoub, B.D. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 2008, 14(11): 1809-1810
50. Lackenby, A., Thompson, C.I., Democratis, J. The potential impact of neuraminidase inhibitor resistant Influenza. Curr Opin Infect Dis 2008, 21(6): 626-638
51. Hauge, S.H., Dudman, S., Borgen, K., Lackenby, A., Hungnes, O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009, 15(2): 155-162
52. Tamura, D., Mitamura, K., Yamazaki, M. et al. Oseltamivir-resistant influenza A viruses circulating in Japan. J Clin Microbiol 2009, 47(5): 1424-1427
53. Centre for Disease Control. Antiviral drugresistant strains of seasonal influenza virus. http://www.cdc.gov/flu/professionals/antivirals/resistance.htm. Accessed January 12, 2010.
54. Cheng, P.K., Leung, T.W., Ho, E.C., Leung, P.C., Ng, A.Y., Lai, M.Y., Lim, W.W. Oseltamivirand amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 2009, 15(6): 966-968
55. García, J., Sovero, M., Torres, A.L. Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers. Influenza Other Respi Viruses 2009, 3(2): 69-74.
56. Centre for Disease Control. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR, 58(35): 969-972
57. World Health Organization, http://www.who.int/csr/disease/swineflu/ frequently-asked-questions/en/index.html. Accessed January, 12, 2010.
58. Poland, CA., Jacobson, R.M., Ovsyan-nikova, LC Influenza virus resistance to antiviral agents: A plea for rational use. Clin Infect Dis 2009, 48(9): 1254-1256
59. Wu, J.T., Leung, G.M., Lipsitch, M., Cooper, B.S., Riley, S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 2009, 6: e1000085.
60. Shay, D.K., Ridenhour B.J. Can we "hedge" against the development of antiviral resistance among pandemic influenza viruses? Plos Med 2009, 6(6): e1000103.
61. Nguyen, H.T., Le, L., Truong, T.N. Top-hits for A/H1N1 identified by virtual screening using ensemble-based docking. Version 3. PLoS Currents Influenza 2009 Sep 3 [revised 2009 Sep 7]:RRN1030.
62. Maggon, K. Peramivir: Emergency use in 2009 H1N1 influenza? Version 32. Knol(TM). http://knol. google, com/k/krishan-mag-gon/peramivir-emergency-use-in- 2009-Mn1/3fy5eowy8suq3/74. Accessed October 22, 2009.
63. Yamashita, M., Tomozawa, T, Kakuta, M., Tokumitsu, A., Nasu, H., Kubo, S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009, 53(1): 186-192
64. Lowen, A.C., Palese, P. Influenza virus transmission: Basic science and implications for the use of antiviral drugs during a pandemic. Infect Disord Drug Targets 2007, 7(4): 318-328
65. Baz, M., Abed, Y., Nehmé, B., Boivin, G. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. Antimicrob Agents Chemother 2009, 53(2): 791-793
66. Hung, H.C., Tseng, C.P, Yang, J.M. Aurintri-carboxylic acid inhibits influenza virus neuraminidase. Antiviral Res 2009, 81(2): 123-131
67. Rossignol, J.F., La Frazia, S., Chiappa, L., Ciucci, A., Santoro, M.C Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009, 284(43): 29798-808.
68. Smee, D.F., Hurst, B.L., Egawa, H., Takahashi, K., Kadota, T, Furuta, Y Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 2009, 64(4): 741-746
69. Roschek, B. Jr., Fink, RC, McMichael, M.D., Li, D., Alberte, R.S. Elderberry flavonoids bind to and prevent H1N1 infection in vitro. Phytochemistry 2009, 70(10): 1255-1261
70. Wirotesangthong, M., Nagai, T, Yamada, H., Amnuoypol, S., Mungmee, C. Effects of Clinacanthus siamensis leaf extract on influenza virus infection. Microbiol Immunol 2009, 53(2): 66-74.
71. Liu, Z., Guo, Z., Wang, G. et al. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 vims infection in BALB/c mice. Eur J Pharm Sci 2009, 38(3): 215-223
72. Chan, R.W.Y, Chan, M.C.W., Wong, ACN. et al. DAS181 inhibits H5N1 influenza vims infection of human lung tissues. Antimicrob Agents Chemother 2009, 53(9): 3935-3941
73. Beigel, J., Bray, M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2009, 78(1): 91-102.